Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma
- 12 February 2009
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 279 (1), 30-38
- https://doi.org/10.1016/j.canlet.2009.01.019
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Hepatocellular carcinomaThe Lancet, 2003
- Les récepteurs à Epidermal Growth Factor (REGF), une nouvelle cible thérapeutiqueCancer/Radiothérapie, 2003
- Vascularization of small hepatocellular carcinomas: correlation with differentiationLiver International, 1999
- Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID miceInternational Journal of Cancer, 1998
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisNew England Journal of Medicine, 1996
- Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcomeJournal of Hepatology, 1993
- Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic PatientsAnnals of Surgery, 1993
- Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors.Molecular and Cellular Biology, 1988